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Purpose: Robot-assisted radical prostatectomy with pelvic lymph node dissection (RALP-PLND) is a feasible treatment option 
for high-risk prostate cancer (HPCa), but remains controversial for very high-risk prostate cancer (VHPCa). We aimed to assess the 
feasibility of RALP-PLND in men ≥70 years with VHPCa features by comparing outcomes to those of HPCa.
Methods: Among patients aged ≥70 years who underwent RALP-PLND between 2005 and 2012, 101 HPCa patients (31%) (PSA≥20 
ng/mL or biopsy Gleason 8–10 or cT3a) and 53 VHPCa patients (16%) (≥cT3b or cN1) were identified. Perioperative, functional, and 
oncological outcomes were compared between groups.
Results: Perioperative outcomes including operative time (P=0.917), estimated blood loss (P=0.181), and complications (P=0.239) 
were comparable. Due to Gleason score downgrading, 19% of HPCa and 4% of VHPCa were actually of intermediate risk. VHPCa 
revealed higher LN involvements (P=0.002). Discrepancy between clinical and pathological nodal status was more frequent in VHPCa 
(36% vs. 7%, P<0.01). Nodal metastasis would have been missed in 23% patients without PLND, while 13% of cN1 patients were shown 
to be metastasis-free by PLND. Continence rates were lower for VHPCa (32% vs. 56%, P=0.013). Although biochemical recurrence-free 
survival rates were comparable (P=0.648), risk for later adjuvant treatments was higher for VHPCa patients (14% vs. 34%, P<0.01).
Conclusions: RALP-PLND is a feasible option for VHPCa in elderly patients with satisfactory oncologic outcomes; however, functional 
outcomes were not as favorable. Patients who are unable to accept the risk of adjuvant therapy and its side effects or incontinence 
should be deterred from surgical treatment, and other options such as radiation therapy could be an alternative.
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INTRODUCTION
Prostate cancer (PCa) is the most common malignancy 
among elderly men and the second most common cause of 
cancer-related death in industrialized nations [1]. Men aged 
≥70 years are known to harbor higher grade cancer with more 
aggressive features than their younger counterparts [2]. In the 
context of demographic shifts in the Korean population, the 
life expectancy has exponentially increased in recent years, as 
a 70-year-old man today will still have a life expectancy of 13.8 
years. With this increase, the percentage of the population 
aged ≥ 60 years is projected to increase from 11.4% in 2011 to 
an estimated 40.1% by 2060 [3]. In line with this expeditious 
demographic change, age at diagnosis will be higher, and 
more cases are likely to present high risk features.
 Radical prostatectomy (RP) is the preferred treatment op-
tion for localized PCa that provides oncological control by 
decreasing the risks of metastasis and local tumor progres-
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2. Operative technique
All RALP was performed via a transperitoneal approach with 
the extent of PLND being based upon the risk and extent of 
disease. Standard PLND included the external and obtura-
tor fossa area, while extended PLND included the intrapelvic 
area (obturator, internal and external iliac) and the common 
iliac area up to the ureteric crossings. Nerve-sparing pro-
cedures were performed when cancer lesions were single-
sided. The perioperative data analyzed included operative 
time, estimated blood loss (EBL), and transfusion rates. Com-
plications were categorized according to the Clavien-Dindo 
classification.
3. Pathological findings
Pathologic factors analyzed included biopsy and prostatec-
tomy Gleason scores, lymphovascular and perineural inva-
sion, positive surgical margin (PSM) status, seminal vesicle 
(SV), and lymph node (LN) involvement. Clinical stage was 
determined according to the 7th American Joint Committee 
on Cancer TNM system.
4. Follow-up
PSA measurements were monitored every three months 
for the first year and semiannually thereafter. Biochemical 
recurrence (BCR) was defined as the first of two or more con-
secutive increases in PSA > 0.2 ng/mL at least three months 
after surgery. Continence was defined as using less than one 
safety liner per day at 12 months. The timing and intervals 
of adjuvant multimodal treatments were applied according 
to surgeon’s discretion based upon the gravity and extent of 
disease, in consideration of patient’s quality of life and life ex-
pectancy.
5. Statistical analysis
Comparisons between groups were assessed by the two-
sided Mann-Whitney U-test for the analysis of continuous 
variables, and the chi-square test for analysis of two or more 
variables. The probability of BCR-free survival (BCRFS) was 
estimated and compared using the Kaplan-Meier method. 
Statistical analyses were performed using PASW Statistics ver. 
18.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
1. Demographic and perioperative characteristics
The two risk groups showed comparable demographic char-
acteristics including age, body mass index, prostate volume, 
American Society of Anesthesiologists category, and admin-
sion [4]. Although RP is considered feasible as first-choice of a 
multidisciplinary strategy for high-risk PCa (HPCa), its role in 
very high-risk PCa (VHPCa) is debatable. With advancements 
in surgical techniques, studies have suggested that RP with 
pelvic lymph node dissection (PLND) allows for excellent 
long-term cancer control for HPCa with cancer-specific and 
overall survival rates comparable to radiation and hormone 
combined therapy and higher rates than radiation alone [5]. 
However, the optimal upper age limit for RP has not been 
clearly defined, with the current recommendation that at least 
a 10-year life expectancy should be a prerequisite for an at-
tempted curative therapy [6]. However, with the growth of the 
elderly population, more men diagnosed with PCa will pres-
ent higher performance status with less comorbidities, sug-
gesting their suitability as candidates for surgery. Thus, in the 
near future, calls for reconsideration of therapeutic options for 
HPCa or VHPCa in elderly men will become more common, 
as more healthy elderly patients will be considered for surgery 
among different multidisciplinary options.
 It has been reported that robot-assisted laparoscopic radi-
cal prostatectomy with PLND (RALP-PLND) allows favorable 
outcome in elderly men with HPCa; however, there have been 
no reports regarding VHPCa [7-9]. The objective of this study 
was to assess the feasibility of RALP-PLND as a first-choice 
treatment for VHPCa patients by comparing surgical, onco-
logic, and continence outcomes to those of HPCa patients.
MATERIALS AND METHODS
1. Patient population
From a cohort of 1,201 men who underwent RALP-PLND with 
or without neoadjuvant therapy by a single surgeon (K.H.R.) 
between July 2005 and December 2012, data of 325 men (27%) 
aged ≥70 years were retrospectively reviewed. Staging evalu-
ations included preoperative serum prostate-specific antigen 
(PSA) level, biopsy Gleason grade, computed tomography (CT) 
or magnetic resonance imaging (MRI), and a bone scan. Pa-
tients were classified into HPCa and VHPCa according to the 
National Comprehensive Cancer Network (NCCN) criteria [10]: 
101 (31%) HPCa, i.e., PSA≥20 ng/mL or a biopsy Gleason 8–10 
or a cT3a disease, and 53 (16%) VHPCa, i.e., ≥cT3b or cN1 dis-
ease. There were no patients with distant metastasis who were 
treated by RALP. A detailed explanation of the therapeutic ef-
fects of RALP for HPCa and VHPCa, and potential for adjuvant 
treatments was provided prior to obtaining consent from all 
patients. Collection of retrospective data of the study was ap-
proved by the Institutional Ethics Committee after review of 
the protocol and procedures employed (2009-0131-001).
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2. Pathologic characteristics
Pathologic characteristics of both groups are shown in Table 
2. VHPCa patients had higher Gleason grades on final pathol-
ogy (P= 0.007), whereas distributions of biopsy grades were 
similar. When the rates of Gleason upgrading and down-
grading were analyzed within each group, VHPCa patients 
showed significantly less rates of downgrading compared to 
HPCa patients (9% vs. 32%, P= 0.001). Tumor volumes, PSM 
rates, and lymphovascular and perineural invasion rates were 
comparable between the groups (P> 0.05). However, VHPCa 
patients had more SV invasion (23% vs. 7%, P= 0.005) and LN 
involvement (25% vs. 7%, P= 0.002), even though LN yields 
were comparable (15.3 ± 7.9 vs. 15.9 ± 7.7, P= 0.663). As shown 
in Table 3, a substantial discrepancy between clinical and 
pathologic nodal status was noted. Among VHPCa patients, 
nodal metastasis would have been missed in 12 patients 
(23%) if PLND had not been performed. On the other hand, 
seven patients (13%) who were suspected of LN metastasis 
were proven to be metastasis-free by PLND.
istration of neoadjuvant hormone therapy (Table 1). There 
were no disparities regarding perioperative characteristics, 
i.e., operative time, EBL, rates of transfusion, nerve sparing, 
or LN dissection. There were no complications of grades ≥ IV 
during surgery or throughout the postoperative period. Rec-
tal injuries occurred in one (2%) and two patients (2%) in the 
VHPCa and HPCa group, respectively. All were primarily re-
paired without the necessity of colostomy. Although a total of 
six (4%) lymphoceles and lymphedemas were observed, none 
were severe enough to require drainage procedures. Bladder 
neck contracture was observed in one VHPCa patient at 11 
months, and was successfully managed by an endoscopic in-
cision. The most common complication was inguinal hernia, 
probably due to the high-age cohort. One (2%) VHPCa and 
three (3%) HPCa patients received surgical repair due to her-
nia symptoms. In overall, there were no statistical differences 
in the rate of all Clavien-Dindo categories between groups 
(P= 0.239), with the majority of complications being minor.
Table 1. Perioperative characteristics 
Characteristic
High-risk
 (n=101)
Very high-risk 
(n=53)
P-value
Age (yr) 73.2 (71–75) 73.5 (71–75) 0.594
Body mass index (kg/m2) 23.9 (22.2–25.4) 23.6 (21.7–25.3) 0.448
Preoperative PSA (ng/mL) 16.8 (6.3–21.7) 26.3 (8.1–35.3) <0.001
Prostate volume (gm) 38.2 (25.4–47.1) 38.4 (24.6–43.8) 0.928
ASA category
   1
   2
45 (60)
30 (40)
25 (52)
23 (48)
0.501
Neoadjuvant 
   hormone therapy
20 (26) 18 (36) 0.139
Nerve sparing
   No
   Unilateral
   Bilateral
13 (19)
11 (17)
43 (64)
6 (17)
4 (11)
25 (72)
0.729
Lymph node dissection
   Standard
   Extended
49 (66)
25 (33)
28 (60)
19 (41)
Operative time (min) 199.1 (168–219) 200.1 (170–230) 0.917
Estimated blood loss (mL) 284.2 (150–400) 347.4 (200–500) 0.181
Complicationsa) 13 (12) 9 (15) 0.239
   Grade I
      Lymphedema/
      lymphocele
4 (4) 2 (4)
   Grade II
      Transfusion 
1 (1) 1 (2)
   Grade III
      Bladder neck contracture
      Inguinal hernia
      Rectal injury
0 (0)
6 (6)
2 (2)
1 (2)
4 (8)
1 (2)
Values are presented as median (interquartile range) and number (%).
PSA, prostate-specific antigen; ASA, American Society of Anesthesiolo-
gists.
a)Complications are categorized by the Clavien-Dindo classification.
Table 2. Perioperative characteristics 
Characteristic
High-risk
 (n=101)
Very high-risk 
(n=53)
P-value
% Cores positive at biopsy 33.3 (16.7–50) 55.8 (30–85.7) <0.001
Biopsy Gleason sum
  ≤6
  7
  ≥8
20 (20)
25 (25)
55 (55)
10 (19)
11 (21)
31 (60)
0.258
Pathologic Gleason sum
  ≤6
  7
  ≥8
10 (10)
51 (52)
38 (38)
3 (6)
21 (40)
29 (54)
0.007
Upgrading 26 (26) 14 (26) 0.904
Downgrading 33 (32) 5 (9) 0.001
Positive surgical margin 47 (47) 43 (60) 0.103
Tumor volume 4.1 (0.9–4.5) 5.5 (1.5–8.7) 0.239
Seminal vesicle invasion 7 (7) 12 (23) 0.005
Lymph node involvement 7 (7) 13 (25) 0.002
Lymph node yield 15.3 (9–21) 15.9 (11–21) 0.663
Lymphovascular invasion 11 (11) 7 (13) 0.656
Perineural invasion 65 (65) 34 (65) 0.962
Values are presented as median (interquartile range) and number (%).
Table 3. Discrepancies between clinical and pathologic lymph 
nodal status
pN0 pN1
High risk
   cN0
   cN1
 
94 (93)
0 (0)
7 (7)
0 (0)
Very-high risk
   cN0
   cN1
31 (58)
7 (13)
12 (23)
3 (6)
Values are presented as number (%).
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3. Follow-up characteristics
Median follow-up period for HPCa and VHPCa patients were 
31.1 and 36.1 months, respectively. Overall BCRFS rates of 
VHPCa and HPCa patients were 58% and 77%, respectively 
(Fig. 1) (P=0.648), with no difference in the time to BCR (13.3 
months vs. 12.4 months, P= 0.803). However, higher rates of 
adjuvant treatments were noted for VHPCa patients com-
pared with HPCa patients (38% vs. 15%, P<0.001). The rate of 
urinary continence was lower in VHPCa patients at 12 months 
(32% vs. 56%, P=0.013), although there were no differences in 
the incidence of either previous TURP or bladder neck recon-
struction during RALP (Table 4).
DISCUSSION
Key determinants to consider when deciding upon PCa 
treatment are Gleason grade, PSA level, and remaining life 
expectancy [11]. The optimal treatment for HPCa in elderly 
men is especially controversial given the heterogeneous na-
ture of PCa in this particular group [12]. The traditional view 
is that the outcomes of surgery in these risk settings do not 
surpass those of radiation or hormone monotherapy, with 
combined therapy accepted as the preferred treatment [13]. 
However, recent data suggest that surgery has expanded its 
indications to higher risk settings and that it yields long-term 
cancer control comparable to radiation and hormone com-
bined therapy, and higher than radiation alone [5,13,14]. We 
expanded upon these studies in terms of surgical, functional, 
and oncologic outcomes to assess the feasibility of RALP-
PLND as a first-choice among multidisciplinary treatments in 
elderly men with VHPCa.
 The optimal upper age limit for surgery in PCa is not clearly 
defined. The current recommendation is that a 10-year life ex-
pectancy should be a prerequisite for attempted curative ther-
apy due to the perception that elderly men are unlikely to gain 
benefit [15]. In fact, rates of RP have been shown to decline 
in patients aged ≥ 70 years [2]. However, with an exponential 
increase in life expectancy, these men are expected to have 
more than a 13-year remaining life expectancy and are thus 
likely to present higher performance status and less comor-
bidities at diagnosis. With this demographic shift, Albertsen 
et al. [16] observed that men aged ≥ 70 years with HPCa are 
likely to have higher morbidity and mortality from their can-
cer than from other causes without curative treatment.
 It is noteworthy that the elderly population shows param-
eters consistent with aggressive disease, with higher grade 
and lower prevalence of organ-confined disease than their 
younger counterparts [17]. It has been reported that poten-
tially curative therapy may confer gain in life expectancy for 
poorly differentiated PCa even for men upto the age of 75 
[15]. Hence, old age should not be the sole criterion to rule 
out curative therapy. Rather, the focus should be on gaining 
control of the cancer, as these patients with Gleason score ≥ 8, 
are significantly at risk of morbidity or mortality from disease 
progression as opposed to other causes. Within a high-risk 
setting, recent studies have reported 5- and 10-year BCRFS 
rates to range from 45% to 62% and 43% to 51%, respectively 
[5,18]. Although studies lacked homogeneity with respect 
to study settings, the 3-year BCRFS rates of our VHPCa and 
HPCa groups fell safely into the range of these studies. A bias 
exists when our results are compared, in that the definition 
of HPCa was different; most prior studies have defined it as 
Fig. 1. Kaplan-Meier curves for biochemical recurrence (BCR)-
free survival of patients with high risk and very-high risk pros-
tate cancer. HPCa, high-risk prostate cancer; VHPCa, very high-
risk prostate cancer.
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Table 4. Follow-up characteristics
Characteristic
High-risk 
(n=101)
Very high-risk 
(n=53)
P-value
Follow-up period 31.1 (17.9–41.9) 36.1 (24.7–49.9) 0.053
Continent at 12 months 38 (56) 14 (32) 0.013
Overall BCR-free survival 78 (77) 31 (58) 0.648
Time to BCR 13.3 (5.5–17.5) 12.4 (2.1–24.1) 0.803
Adjuvant treatment
   Hormone
   Radiation
   Both
11 (11)
2 (2)
2 (2)
14 (26)
2 (4)
2 (4)
<0.001
Values are presented as median (interquartile range) and number (%).
BCR, biochemical recurrence.
Vol. 2 / No. 3 / September 2014
131
PROSTATE INTERNATIONAL
http://dx.doi.org/10.12954/PI.14050
≥ T2c, whereas we used ≥ T3a as the definition. Therefore, 
presuming that our results did not overestimate BCRFS rates, 
we believe the benefit of RALP-PLND in VHPCa is compa-
rable to that of HPCa. 
 Accurate Gleason grading is an important determinant 
for staging evaluation and planning of future management. 
However, a downgrading rate of 20% and an upgrading rate 
of 9% to 27% have been reported for cT3 disease [5,13]. If ac-
curate biopsy grades were reported for our patients, 19% of 
HPCa and 4% of VHPCa patients would have fallen into the 
intermediate risk group; accordingly, only 9% of patients 
in our overall cohort had developed BCR. Considering that 
surgery is the only treatment that allows for Gleason grade 
restaging, the general exclusion of these risk groups from sur-
gery may have placed them at risk of adverse effects implicit 
with adjuvant therapy.
 Radiographically diagnosed metastatic LNs in VHPCa pose 
a dilemma regarding the selection of optimal therapy [19]. 
Many clinicians recommend hormone therapy and are reluc-
tant to suggest definitive local therapy [20]. However, recent 
data suggest that debulking of the primary tumor with PLND 
could improve cancer-specific and overall survival by means 
of regional disease control [14]. Bader et al. [21] proposed that 
there is heterogeneity in the degree of metastasis and that 
patients with a minimal extent of metastasis may benefit from 
meticulous PLND. Moreover, patients who received surgery 
for metastatic PCa were shown to have better response and 
survival outcomes upon adjuvant hormonal ablation [14].
 Inaccuracy of imaging modalities in detecting LN metas-
tasis is another limitation that precludes surgery in cases of 
nonmetastatic VHPCa [19]. While patients misinterpreted 
as having positive nodes would have immediately started 
systemic therapy if PLND had not been performed, those 
without evidence of LN metastasis can be observed to deter-
mine when or if at all adjuvant therapy is needed. In contrast, 
patients proven to have nodal metastasis by PLND can be 
considered for early adjuvant therapy. Overall, RALP-PLND 
could be considered as the standard for accurate nodal stag-
ing and local disease control, especially for LN metastatic 
patients. 
 In the context of post-RALP functional outcomes in the 
elderly population, studies have reported 1-year continence 
rates of men aged 60, 70, and 75 to be 53%, 63%, and 46%, 
respectively [18,22]. However, these results need to be in-
terpreted with caution, considering various definitions of 
continence and the distinct populations utilized in assessing 
outcomes. By defining continence as requiring less than one 
safety liner per day, rates of the HPCa group were comparable 
to those of prior studies [18,22]. However, VHPCa patients 
showed lower rates, probably in part due to aggressive extra-
fascial approaches along with wider bladder neck resections. 
 We note that our study had several limitations. First was 
the small number of the cohort due to patient selection of a 
single surgeon. Furthermore, surgeries performed by a single 
high-volume surgeon may have affected treatment outcomes, 
as several studies have reported that BCR is associated with 
surgical experience [23]. Second, the cohort may not repre-
sent all men with HPCa and VHPCa, due to the selection of 
relatively healthy patients aged ≥ 70 years who were willing 
to undergo surgery even when given multidisciplinary treat-
ment options. Therefore, our findings may not hold true for 
the younger counterpart. Third, the NCCN risk stratification 
criteria for HPCa or VHPCa are one of many definitions to 
date, causing heterogeneity in the comparison of outcomes of 
prior studies. Fourth, the learning curve of the surgeon dur-
ing the study period of eight years was not accounted for in 
the analysis; thus, surgical and oncologic outcomes may have 
been affected by such confounder. Lastly, our thesis stands 
on the solid hypothesis that surgery is a feasible treatment op-
tion for HPCa; however, without well-designed randomized 
control trials, the question whether these patients will benefit 
from RALP-PLND in terms of both oncological and functional 
results will need to be further investigated.
 In conclusion, RALP-PLND is a feasible option for elderly 
patients with VHPCa in terms of surgical and oncological 
outcomes, but not functional outcomes. Our data will assist in 
preoperative counseling of elderly patients, whereas those who 
are unable to accept the higher risk of adjuvant therapy and its 
related side effects and incontinence would need to consider 
alternate treatment options such as radiation therapy.
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